Simnova Biotherapeutics
Simnova holds Greater China development and commercialization rights for partnered Orna in vivo cell therapies. The January 2025 expansion adds BCMA to the circular RNA partnership. Territorial participation is retained without counting the partnered programs as unrelated inventions; current clinical stage was not verified.
Corporate information
- Company entity
- Simnova Biotherapeutics
- Headquarters / principal office
- No verified public location identified
- Founded
- 2019 (independent since 2021) ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.simnovabio.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Simnova holds Greater China development and commercialization rights for partnered Orna in vivo cell therapies. The January 2025 expansion adds BCMA to the circular RNA partnership. Territorial participation is retained without counting the partnered programs as unrelated inventions; current clinical stage was not verified.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Simnova Biotherapeutics — primary program / ownership disclosure
- Founding / incorporation disclosure — scope stated in field